Type 1 DiabetesNCT06496412
Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM
A study testing fecal microbiota transplantation in people with Type 1 Diabetes, run by Second Xiangya Hospital of Central South University at 1 site in China.
Trial summary
This study is a prospective, single-center, parallel-design,1:1 randomized controlled trial with triple blinding. It aims to investigate the effects of fecal microbiota transplantation (FMT) on cognitive function in patients with long-term type 1 diabetes (T1D), as well as its effects on other complications, glycemic… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Type 1 Diabetes
- What is being tested?
- fecal microbiota transplantation
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteChina
- Study dates
- 20 Apr 2024to 30 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- According to the definition of type 1 diabetes mellitus (T1DM) by the World Health Organization (WHO), the diagnostic criteria are as follows: (i) clinically diagnosed as T1D by endocrinologists; (ii) insulin dependence from disease onset and diabetic ketoacidosis (DKA)/diabetic ketosis (DK) at diagnosis; (iii) positive for at least one of islet autoantibodies for glutamic acid decarboxylase antibody [GADA], insulinoma-associated protein 2 antibody [IA-2A], and zinc transporter 8 antibody [ZnT8A]; or negative for all three islet autoantibodies, but diagnosed before age 30.
- Age between 18 and 60 years, with a diabetes duration of 10 years or more
- Glycated hemoglobin levels ranging from 6.5% to 9.0%.
Who cannot join
- Use of any hypoglycemic medication other than insulin in the two months prior to randomization.
- Participation in other clinical trials within the two months prior to randomization.
- Use of antimicrobial drugs, probiotics, intestinal microbiota regulators, and other drugs with significant impact on gut microbiota within the two months prior to randomization.
- Gastrointestinal diseases: celiac disease, irritable bowel syndrome, Crohn's disease, etc.
- Severe infections, severe heart, liver, kidney diseases, tumors, and other inflammatory or autoimmune diseases.
- Pregnant or lactating women, or women planning pregnancy during the study period.
Show all 10Show fewer
- Severe mental health disorders such as schizophrenia, major depression, bipolar disorder, alcohol or substance abuse, etc.
- Neurological disorders such as Parkinson's disease, progressive supranuclear palsy, epilepsy, multiple sclerosis, traumatic brain injury, stroke, etc.
- Post-implantation of metal materials or contraindications for other MRI examinations.
- Severe episodes of unconscious hypoglycemia within the past two months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha, Hunan, 410011
Xia Li, MD/PHD, +86 13974885753, lixia2014@vip.163.com
About this study
Official title: Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM: a Randomized Controlled, Triple-blind Clinical Study
This study is a prospective, single-center, parallel-design,1:1 randomized controlled trial with triple blinding. It aims to investigate the effects of fecal microbiota transplantation (FMT) on cognitive function in patients with long-term type 1 diabetes (T1D), as well as its effects on other complications, glycemic control, insulin dosage, insulin resistance, peripheral blood immune cells, serum metabolites, and safety. This study is divided into two phases for recruiting participants. The first phase recruits 10 individuals (experimental group: 5, control group: 5), while the second phase recruits 30 individuals (experimental group: 15, control group: 15).The main research objectives are as follows:
- To observe the difference in cognitive function between the FMT group and the placebo group, with the indicators including cognitive scale scores, changes in brain MRI imaging indicators and brain age at week 24 compared to baseline.
- To observe the difference in other complications between the FMT group and the placebo group, with the indicators including changes in urinary albumin/creatinine ratio, fundus photography, carotid intima-media thickness, and arterial pulse wave velocity at week 24 compared to baseline.
- To observe the difference in glycemic control, insulin dosage, insulin resistance, peripheral blood immune cells, gut microbiota, and serum metabolites between the FMT group and the placebo group.
- To evaluate the safety of FMT.
- Conditions
- Type 1 Diabetes
- Being tested
- fecal microbiota transplantation, Placebo
- Keywords
- type 1 diabetes, fecal microbiota transplantation, cognitive impairment
- Medical subject headings
- Diabetes Mellitus, Type 1, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fecal microbiota transplantationDrug
Take fecal microbiota capsules.
PlaceboDrug
Take placebo capsules.
| Study group | Role | What they receive |
|---|---|---|
| fecal microbiota transplantation | Experimental | On the basis of baseline medication, high-dose fecal microbiota transplantation (FMT) will be administered, with subjects taking 50 fecal microbiota capsules. Subsequently, maintenance doses will be administered at week 2, 4, 8, 12, and 20, with 10 capsules taken each time. Fasting is required 4 hours before and 1 hour after capsule ingestion, and subjects are instructed to maintain a stable diet and physical activity pattern throughout the 24-week study period. Capsules will be transported on ice and warmed for 10 minutes at 37°C before FMT administration. Receives: Drug: fecal microbiota transplantation |
| placebo | Placebo comparator | Different from the experimental group, the control group will receive placebo capsules that have the same appearance as the fecal microbiota capsules, while other procedures remain the same as those in the experimental group. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognition:Comparison of the average change in Z-scores for memory and executive domain-related assessments between the experimental and control groups from baseline to week 24.
The Z-scores of memory and executive domain assessments-related assessments are indicators that can comprehensively reflect cognitive function.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Auditory Verbal Learning Test between the experimental and control groups from baseline to week 24.
The Auditory Verbal Learning Test (AVLT) is a neuropsychological assessment tool used to evaluate an individual's verbal learning and memory skills. This test involves the presentation of a list of words to the test subject, who is then asked to recall as many words as possible from the list after a single exposure. The process is typically repeated several times, allowing the examiner to assess the subject's ability to learn new information and retain it over time.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Trail Making Test Part A and Part B between the experimental and control groups from baseline to week 24.
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts, A and B. Participant is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning.
Results for both TMT A and B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Verbal Fluency Test between the experimental and control groups from baseline to week 24.
The Verbal Fluency Test (VFT) is a common neuropsychological assessment used to evaluate an individual's cognitive flexibility and generative language abilities. It typically involves asking the participant to produce as many words as possible within a certain time limit, usually one minute, that fit a specific criterion.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Boston Naming Test between the experimental and control groups from baseline to week 24.
The Boston Naming Test (BNT) is a widely used neuropsychological instrument designed to assess an individual's confrontational naming abilities, which is a critical aspect of language function. The test consists of a series of line drawings of objects, animals, and people, each paired with a prompt that encourages the participant to name the item.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Stroop Color- Word Association Test between the experimental and control groups from baseline to week 24.
The Stroop Color- Word Association Test is particularly useful in assessing executive functions, such as selective attention and cognitive flexibility. It is sensitive to the effects of various conditions that impact cognitive control, including attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, Parkinson's disease, and substance abuse disorders. The test can also be used to evaluate the effectiveness of cognitive training programs and to monitor changes in cognitive function over time.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Symbol Digit Modalities Test between the experimental and control groups from baseline to week 24.
The Symbol Digit Modalities Test (SDMT) is a brief neuropsychological screening tool designed to assess cognitive processing speed and attention. The SDMT is scored based on the number of correct responses within the time frame, providing a quantitative measure of cognitive performance. It is particularly sensitive to changes in cognitive function that may occur with aging, as well as in conditions such as multiple sclerosis, Parkinson's disease, traumatic brain injury, and Alzheimer's disease. The test is often used to monitor the progression of cognitive decline and to evaluate the effectiveness of treatments.
The SDMT is also valuable in differentiating between different types of cognitive impairments and can be used as part of a comprehensive neuropsychological assessment to provide a more detailed picture of an individual's cognitive strengths and weaknesses. Its brevity and ease of administration make it a practical tool for repeated assessments over time.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Clock drawing test between the experimental and control groups from baseline to week 24.
The Clock Drawing Test (CDT) is a widely used neuropsychological screening tool that assesses an individual's cognitive function, particularly in the areas of executive function, visual-spatial skills, and constructional praxis. It is a simple yet effective test that requires participants to draw a clock face and then set the hands to indicate a specific time, often 10 minutes past 11.
Measured: from baseline to week 24
Cognition: Comparison of the average change in MOCA between the experimental and control groups from baseline to week 24.
The Montreal Cognitive Assessment (MOCA) is a rapid screening tool for mild cognitive dysfunction, particularly useful in identifying early signs of cognitive impairment associated with conditions such as Alzheimer's disease and other forms of dementia.The test is sensitive to changes in cognitive function that may not be detected by less detailed assessments, making it a valuable tool for both clinical and research settings.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Subjective Cognitive Decline 9 between the experimental and control groups from baseline to week 24.
Subjective Cognitive Decline 9 (SCD9) is a tool designed to assess an individual's perception of changes in their cognitive abilities over time. It is particularly useful for identifying early signs of cognitive decline that may be indicative of the onset of neurodegenerative diseases such as Alzheimer's disease.
The development of the SCD9 questionnaire aims to provide a localized, sample-assisted, multi-domain instrument that can be used to evaluate subjective cognitive decline in the elderly population over the past 1-2 years. The scale has demonstrated good reliability and validity, with a confirmatory factor analysis supporting a 4-factor model that includes memory, attention, executive function, and language domains.
Measured: from baseline to week 24
Cognition: Comparison of the average change in Brain MRI between the experimental and control groups from baseline to week 24.
Brain MRI, particularly structural Structural MRI, Diffusion MRI(DTI), and Functional MRI (fMRI), plays a crucial role in understanding cognitive functions. Structural MRI can identify anatomical correlates of cognitive deficits, while DTI provides insights into the integrity of neural pathways essential for cognitive processing. fMRI allows researchers to observe brain activity during various cognitive tasks, offering a direct link between brain function and cognition. This comprehensive approach enables clinicians and researchers to explore the neural basis of cognitive functions and disorders, enhancing diagnosis and treatment strategies.
Measured: from baseline to week 24
Secondary outcomes (27)
Safety: Proportion of participants with treatment-related adverse events, serious adverse events, or adverse events of special interest.
Proportion of participants with treatment-related adverse events, serious adverse events, or adverse events of special interest.
Adverse events, serious adverse events, or adverse events of special interest, will be evaluated following study procedures using AE and SAE forms, telephone and in person interview, and relevant medical records related to adverse events.
Measured: from baseline to week 24
macrovascular complications：Comparison of the average change in Carotid Intima-Media Thickness between the experimental and control groups from baseline to week 24.
Carotid Intima-Media Thickness is a valuable indicator of subclinical atherosclerosis and a predictor of cardiovascular and cerebrovascular events. It is typically measured using high-resolution B-mode ultrasonography, which provides images of the carotid artery walls. The measurement is taken from the leading edge of the lumen-intima interface to the leading edge of the media-adventitia interface on the far wall of the carotid artery.
Measured: from baseline to week 24
macrovascular complications：Comparison of the average change in Arterial Pulse Wave Velocity between the experimental and control groups from baseline to week 24.
Arterial Pulse Wave Velocity (PWV) is a measure of the speed at which blood pressure waves move through the arteries. It is an important indicator of arterial stiffness, with higher values indicating stiffer arteries, which are often associated with cardiovascular risk.
Measured: from baseline to week 24
macrovascular complications：Comparison of the average change in Ankle-Brachial Index between the experimental and control groups from baseline to week 24.
Ankle-Brachial Index (ABI) is a simple, non-invasive test used to assess the presence of peripheral artery disease (PAD). It compares the blood pressure measured at the ankle with the blood pressure measured at the arm (brachial artery).
ABI is also a marker for overall cardiovascular health. A low ABI is associated with an increased risk of heart attack, stroke, and overall cardiovascular mortality.
Measured: from baseline to week 24
microvascular complications：Comparison of the average change in Albumin-to-Creatinine Ratio between the experimental and control groups from baseline to week 24.
Albumin-to-Creatinine Ratio (ACR) is a diagnostic test used to detect and monitor kidney function, particularly to identify early signs of kidney damage. It measures the amount of albumin (a type of protein) in the urine, normalized to the amount of creatinine (a waste product of muscle metabolism) to account for variations in urine concentration.
Measured: from baseline to week 24
microvascular complications：Comparison of the average change in Estimated Glomerular Filtration Rate between the experimental and control groups from baseline to week 24.
Estimated Glomerular Filtration Rate (eGFR) is a key indicator of kidney function. It estimates the rate at which the kidneys filter waste products from the blood, providing valuable information about renal health and helping to diagnose and monitor kidney disease.
Measured: from baseline to week 24
microvascular complications：Compare the differences in the proportion of abnormal fundus photography and the severity of progression between the experimental and control groups during the follow-up period.
Fundus photography is a non-invasive diagnostic procedure used to capture images of the retina at the back of the eye. This technique is essential for the early detection, evaluation, and monitoring of diabetic retinopathy and other vascular changes in the eye, which can be indicative of diabetes-related complications.
Measured: from baseline to week 24
microvascular complications：Comparison of the average change in Neuropathy lmpairment Score in the Lower Limbs between the experimental and control groups from baseline to week 24.
The Neuropathy Impairment Score in the Lower Limbs (NIS-LL) is a clinical tool used to evaluate the severity of neuropathy, specifically in the lower extremities. This score helps in assessing the degree of nerve damage and its impact on motor and sensory functions. The NIS-LL takes into account the following components.
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Hemoglobin A1c between the experimental and control groups from baseline to week 24.
Hemoglobin A1c (HbA1c) is a blood test that measures the average level of blood glucose (sugar) over the past two to three months. It is a key indicator used to diagnose and manage diabetes.
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Time in Range between the experimental and control groups from baseline to week 24.
Time in Range (TIR) is a key metric used in Continuous Glucose Monitoring (CGM) to assess glycemic control in individuals with diabetes. It represents the percentage of time that a person's blood glucose levels stay within a target range over a specified period, typically 24 hours.
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Time Above Range between the experimental and control groups from baseline to week 24.
Time Above Range (TAR) is a crucial metric in Continuous Glucose Monitoring (CGM) used to evaluate how often an individual's blood glucose levels exceed a predefined upper limit. This metric helps in understanding hyperglycemia and its potential impact on health.
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Time Below Range between the experimental and control groups from baseline to week 24.
Time Below Range (TBR) is a critical metric in Continuous Glucose Monitoring (CGM) used to evaluate the duration that an individual's blood glucose levels fall below a predefined lower limit. This metric is crucial for understanding hypoglycemia and its potential risks.
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Glucose Management Indicato between the experimental and control groups from baseline to week 24.
Glucose Management Indicator (GMI) is a metric used in Continuous Glucose Monitoring (CGM) to estimate average blood glucose levels over a specified period. It provides a simplified interpretation of glycemic control based on CGM data.
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Glycemia risk index between the experimental and control groups from baseline to week 24.
Glycemia risk index (GRI), a newly developed composite CGM metric, could evaluate the quality of glycemia by weighting the risk of both hypoglycemia and hyperglycemia, which are associated with long-term complications
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Coefficient of Variation between the experimental and control groups from baseline to week 24.
The Coefficient of Variation (CV) in Continuous Glucose Monitoring (CGM) is a statistical measure used to assess the variability of blood glucose levels over a period of time. It provides insights into the stability and consistency of glucose control.
Measured: from baseline to week 24
Glycemic control：Comparison of the average change in Mean Amplitude of Glycemic Excursions between the experimental and control groups from baseline to week 24.
Mean Amplitude of Glycemic Excursions (MAGE) is a metric used in Continuous Glucose Monitoring (CGM) to quantify the magnitude of glucose fluctuations over a specified period. It provides insights into the variability and stability of blood glucose levels, reflecting how much and how often glucose levels deviate from a baseline.
Measured: from baseline to week 24
Blood lipid：Comparison of the average change in triglycerides between the experimental and control groups from baseline to week 24.
Triglycerides (TG) are the most common form of fat in the human body and serve as an important source of energy. They are a type of lipid, which is a waxy-like fat substance made by the body and obtained from foods that contain fat.
Measured: from baseline to week 24
Blood lipid：Comparison of the average change in total cholesterol between the experimental and control groups from baseline to week 24.
Total Cholesterol (TC) ,which stands for Total Cholesterol, is a blood test that measures the total amount of cholesterol in your blood. Cholesterol is a waxy substance that's vital for the body to function properly. However, too much cholesterol in your blood can lead to health problems, such as heart disease and stroke.
Measured: from baseline to week 24
Blood lipid：Comparison of the average change in high-density lipoprotein cholesterol between the experimental and control groups from baseline to week 24.
High-Density Lipoprotein Cholesterol（HDL-C)）is commonly referred to as "good" cholesterol because high levels of HDL-C are associated with a lower risk of heart disease. HDL-C helps transport cholesterol from other parts of your body back to your liver, where it can be removed from your bloodstream. This process helps keep cholesterol from building up in your arteries, thus reducing the risk of atherosclerosis (hardening or narrowing of the arteries) and cardiovascular events such as heart attacks and strokes. Regular physical activity, a healthy diet, and certain medications can help increase HDL-C levels.
Measured: from baseline to week 24
Blood lipid：Comparison of the average change in low-density lipoprotein cholesterol between the experimental and control groups from baseline to week 24.
Low-Density Lipoprotein Cholesterol (LDL-C) is often referred to as "bad" cholesterol because high levels of LDL-C can lead to the buildup of cholesterol in the arteries, which increases the risk of atherosclerosis (hardening or narrowing of the arteries) and cardiovascular diseases such as heart attacks and strokes. LDL-C transports cholesterol from the liver to various parts of the body. If there is too much LDL-C in the blood, it can deposit on the walls of the arteries, forming plaques that can restrict or block blood flow. Managing LDL-C levels through diet, exercise, and medications is important for cardiovascular health.
Measured: from baseline to week 24
Blood pressure：Comparison of the average change in blood pressure between the experimental and control groups from baseline to week 24.
Blood pressure is the force exerted by circulating blood on the walls of the arteries. It is an essential measure of cardiovascular health and is typically recorded as two numbers: systolic and diastolic pressure.
Systolic Pressure: The higher number, representing the pressure in the arteries when the heart beats and pumps blood.
Diastolic Pressure: The lower number, representing the pressure in the arteries when the heart is at rest between beats.
Measured: from baseline to week 24
Body Mass Index：Comparison of the average change in body mass index between the experimental and control groups from baseline to week 24.
Body Mass Index (BMI) is a widely used measure to assess whether a person has a healthy body weight for a given height. It is a simple calculation that provides an indication of body fatness, which can be related to the risk of developing health problems.
Measured: from baseline to week 24
Insulin resistance: Comparison of the average change in estimated Glucose Disposal Rate between the experimental and control groups from baseline to week 24.
eGDR stands for "estimated Glucose Disposal Rate." It is a metric used to estimate insulin sensitivity, particularly in individuals with diabetes, especially type 1 diabetes. Insulin sensitivity refers to how effectively the body's cells respond to insulin, which is crucial for regulating blood glucose levels.
Measured: from baseline to week 24
Insulin dose: Comparison of the average change in insulin dose between the experimental and control groups from baseline to week 24.
An insulin dose refers to the specific amount of insulin administered to a person with diabetes to help manage their blood glucose levels.
Measured: from baseline to week 24
Change in gut composition: Engraftment of fecal microbial transplant as assessed by 16S rRNA sequencing of recipient stool sample
In order to determine efficacy of fecal transplant, change in composition, i.e. microbial engraftment will be assessed by testing for newly detected operational taxonomic units (OTUs) in the gut microbiome of a participant post-FMT (which were present in the donor but undetected in the participant pre-FMT). This will be assessed via 16S rRNA seq of recipient stool samples pre- and post- FMT.
Measured: from baseline to week 24
Changes in peripheral blood mononuclear cells: Assessing the effects of fecal microbial transplant on peripheral blood mononuclear cells by flow cytometry.
Flow cytometry is a powerful technique used to analyze the characteristics of individual cells in a heterogeneous population. When applied to peripheral blood mononuclear cells (PBMCs), flow cytometry provides detailed insights into the composition and function of various immune cell subsets present in the bloodstream.
Measured: from baseline to week 24
Changes in peripheral blood metabolites: Assessing the impact of fecal microbiota transplantation on peripheral blood metabolites using metabolomics.
Metabolomics is a powerful analytical approach used to comprehensively analyze and quantify small molecules, known as metabolites, present in biological samples. When applied to peripheral blood, metabolomics enables the identification and measurement of a wide range of metabolites that serve as indicators of various physiological processes and metabolic pathways.
Measured: from baseline to week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2024
- Study start20 Apr 2024
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- More trials run by Second Xiangya Hospital of Central South UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xia Li, Second Xiangya Hospital of Central South University
- Investigators
- Xia Li, MD/PHD, Principal investigator, The Second Xiangya Hospital, Central South University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06496412
- Sponsor's protocol ID
- T1D cognitive impairment FMT
- Status last verified
- Jul 2024
- First submitted
- 25 Jun 2024
- Last updated
- 11 Jul 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM: a Randomized Controlled, Triple-blind Clinical Study
- ClinicalTrials.gov ID
- NCT06496412
- Acronym / sponsor ID
- T1D cognitive impairment FMT
- Conditions
- Type 1 Diabetes
- Keywords
- type 1 diabetes, fecal microbiota transplantation, cognitive impairment
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Second Xiangya Hospital of Central South UniversityUniversity, hospital or other
- Study start
- 20 Apr 2024 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 11 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective, single-center, parallel-design,1:1 randomized controlled trial with triple blinding. It aims to investigate the effects of fecal microbiota transplantation (FMT) on cognitive function in patients with long-term type 1 diabetes (T1D), as well as its effects on other complications, glycemic control, insulin dosage, insulin resistance, peripheral blood immune cells, serum metabolites, and safety. This study is divided into two phases for recruiting participants. The first phase recruits 10 individuals (experimental group: 5, control group: 5), while the second phase recruits 30 individuals (experimental group: 15, control group: 15).The main research objectives are as follows:
- To observe the difference in cognitive function between the FMT group and the placebo group, with the indicators including cognitive scale scores, changes in brain MRI imaging indicators and brain age at week 24 compared to baseline.
- To observe the difference in other complications between the FMT group and the placebo group, with the indicators including changes in urinary albumin/creatinine ratio, fundus photography, carotid intima-media thickness, and arterial pulse wave velocity at week 24 compared to baseline.
- To observe the difference in glycemic control, insulin dosage, insulin resistance, peripheral blood immune cells, gut microbiota, and serum metabolites between the FMT group and the placebo group.
- To evaluate the safety of FMT.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| fecal microbiota transplantation | Experimental | Drug: fecal microbiota transplantationOn the basis of baseline medication, high-dose fecal microbiota transplantation (FMT) will be administered, with subjects taking 50 fecal microbiota capsules. Subsequently, maintenance doses will be administered at week 2, 4, 8, 12, and 20, with 10 capsules taken each time. Fasting is required 4 hours before and 1 hour after capsule ingestion, and subjects are instructed to maintain a stable diet and physical activity pattern throughout the 24-week study period. Capsules will be transported on ice and warmed for 10 minutes at 37°C before FMT administration. |
| placebo | Placebo comparator | Drug: PlaceboDifferent from the experimental group, the control group will receive placebo capsules that have the same appearance as the fecal microbiota capsules, while other procedures remain the same as those in the experimental group. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- According to the definition of type 1 diabetes mellitus (T1DM) by the World Health Organization (WHO), the diagnostic criteria are as follows: (i) clinically diagnosed as T1D by endocrinologists; (ii) insulin dependence from disease onset and diabetic ketoacidosis (DKA)/diabetic ketosis (DK) at diagnosis; (iii) positive for at least one of islet autoantibodies for glutamic acid decarboxylase antibody [GADA], insulinoma-associated protein 2 antibody [IA-2A], and zinc transporter 8 antibody [ZnT8A]; or negative for all three islet autoantibodies, but diagnosed before age 30.
- Age between 18 and 60 years, with a diabetes duration of 10 years or more
- Glycated hemoglobin levels ranging from 6.5% to 9.0%.
Key exclusion criteria (10 listed)
- Use of any hypoglycemic medication other than insulin in the two months prior to randomization.
- Participation in other clinical trials within the two months prior to randomization.
- Use of antimicrobial drugs, probiotics, intestinal microbiota regulators, and other drugs with significant impact on gut microbiota within the two months prior to randomization.
- Gastrointestinal diseases: celiac disease, irritable bowel syndrome, Crohn's disease, etc.
- Severe infections, severe heart, liver, kidney diseases, tumors, and other inflammatory or autoimmune diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fecal microbiota transplantationTake fecal microbiota capsules. | Drug | fecal microbiota transplantation |
| PlaceboTake placebo capsules. | Drug | placebo |
Primary outcome
Cognition:Comparison of the average change in Z-scores for memory and executive domain-related assessments between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Z-scores of memory and executive domain assessments-related assessments are indicators that can comprehensively reflect cognitive function.
Cognition: Comparison of the average change in Auditory Verbal Learning Test between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Auditory Verbal Learning Test (AVLT) is a neuropsychological assessment tool used to evaluate an individual's verbal learning and memory skills. This test involves the presentation of a list of words to the test subject, who is then asked to recall as many words as possible from the list after a single exposure. The process is typically repeated several times, allowing the examiner to assess the subject's ability to learn new information and retain it over time.
Cognition: Comparison of the average change in Trail Making Test Part A and Part B between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts, A and B. Participant is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning. Results for both TMT A and B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.
Cognition: Comparison of the average change in Verbal Fluency Test between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Verbal Fluency Test (VFT) is a common neuropsychological assessment used to evaluate an individual's cognitive flexibility and generative language abilities. It typically involves asking the participant to produce as many words as possible within a certain time limit, usually one minute, that fit a specific criterion.
Cognition: Comparison of the average change in Boston Naming Test between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Boston Naming Test (BNT) is a widely used neuropsychological instrument designed to assess an individual's confrontational naming abilities, which is a critical aspect of language function. The test consists of a series of line drawings of objects, animals, and people, each paired with a prompt that encourages the participant to name the item.
Cognition: Comparison of the average change in Stroop Color- Word Association Test between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Stroop Color- Word Association Test is particularly useful in assessing executive functions, such as selective attention and cognitive flexibility. It is sensitive to the effects of various conditions that impact cognitive control, including attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, Parkinson's disease, and substance abuse disorders. The test can also be used to evaluate the effectiveness of cognitive training programs and to monitor changes in cognitive function over time.
Cognition: Comparison of the average change in Symbol Digit Modalities Test between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Symbol Digit Modalities Test (SDMT) is a brief neuropsychological screening tool designed to assess cognitive processing speed and attention. The SDMT is scored based on the number of correct responses within the time frame, providing a quantitative measure of cognitive performance. It is particularly sensitive to changes in cognitive function that may occur with aging, as well as in conditions such as multiple sclerosis, Parkinson's disease, traumatic brain injury, and Alzheimer's disease. The test is often used to monitor the progression of cognitive decline and to evaluate the effectiveness of treatments. The SDMT is also valuable in differentiating between different types of cognitive impairments and can be used as part of a comprehensive neuropsychological assessment to provide a more detailed picture of an individual's cognitive strengths and weaknesses. Its brevity and ease of administration make it a practical tool for repeated assessments over time.
Cognition: Comparison of the average change in Clock drawing test between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Clock Drawing Test (CDT) is a widely used neuropsychological screening tool that assesses an individual's cognitive function, particularly in the areas of executive function, visual-spatial skills, and constructional praxis. It is a simple yet effective test that requires participants to draw a clock face and then set the hands to indicate a specific time, often 10 minutes past 11.
Cognition: Comparison of the average change in MOCA between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
The Montreal Cognitive Assessment (MOCA) is a rapid screening tool for mild cognitive dysfunction, particularly useful in identifying early signs of cognitive impairment associated with conditions such as Alzheimer's disease and other forms of dementia.The test is sensitive to changes in cognitive function that may not be detected by less detailed assessments, making it a valuable tool for both clinical and research settings.
Cognition: Comparison of the average change in Subjective Cognitive Decline 9 between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Subjective Cognitive Decline 9 (SCD9) is a tool designed to assess an individual's perception of changes in their cognitive abilities over time. It is particularly useful for identifying early signs of cognitive decline that may be indicative of the onset of neurodegenerative diseases such as Alzheimer's disease. The development of the SCD9 questionnaire aims to provide a localized, sample-assisted, multi-domain instrument that can be used to evaluate subjective cognitive decline in the elderly population over the past 1-2 years. The scale has demonstrated good reliability and validity, with a confirmatory factor analysis supporting a 4-factor model that includes memory, attention, executive function, and language domains.
Cognition: Comparison of the average change in Brain MRI between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Brain MRI, particularly structural Structural MRI, Diffusion MRI(DTI), and Functional MRI (fMRI), plays a crucial role in understanding cognitive functions. Structural MRI can identify anatomical correlates of cognitive deficits, while DTI provides insights into the integrity of neural pathways essential for cognitive processing. fMRI allows researchers to observe brain activity during various cognitive tasks, offering a direct link between brain function and cognition. This comprehensive approach enables clinicians and researchers to explore the neural basis of cognitive functions and disorders, enhancing diagnosis and treatment strategies.
27 secondary outcomes
Safety: Proportion of participants with treatment-related adverse events, serious adverse events, or adverse events of special interest.
Time frame: from baseline to week 24
macrovascular complications：Comparison of the average change in Carotid Intima-Media Thickness between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
macrovascular complications：Comparison of the average change in Arterial Pulse Wave Velocity between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
macrovascular complications：Comparison of the average change in Ankle-Brachial Index between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
microvascular complications：Comparison of the average change in Albumin-to-Creatinine Ratio between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
microvascular complications：Comparison of the average change in Estimated Glomerular Filtration Rate between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
microvascular complications：Compare the differences in the proportion of abnormal fundus photography and the severity of progression between the experimental and control groups during the follow-up period.
Time frame: from baseline to week 24
microvascular complications：Comparison of the average change in Neuropathy lmpairment Score in the Lower Limbs between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Hemoglobin A1c between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Time in Range between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Time Above Range between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Time Below Range between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Glucose Management Indicato between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Glycemia risk index between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Coefficient of Variation between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Glycemic control：Comparison of the average change in Mean Amplitude of Glycemic Excursions between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Blood lipid：Comparison of the average change in triglycerides between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Blood lipid：Comparison of the average change in total cholesterol between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Blood lipid：Comparison of the average change in high-density lipoprotein cholesterol between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Blood lipid：Comparison of the average change in low-density lipoprotein cholesterol between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Blood pressure：Comparison of the average change in blood pressure between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Body Mass Index：Comparison of the average change in body mass index between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Insulin resistance: Comparison of the average change in estimated Glucose Disposal Rate between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Insulin dose: Comparison of the average change in insulin dose between the experimental and control groups from baseline to week 24.
Time frame: from baseline to week 24
Change in gut composition: Engraftment of fecal microbial transplant as assessed by 16S rRNA sequencing of recipient stool sample
Time frame: from baseline to week 24
Changes in peripheral blood mononuclear cells: Assessing the effects of fecal microbial transplant on peripheral blood mononuclear cells by flow cytometry.
Time frame: from baseline to week 24
Changes in peripheral blood metabolites: Assessing the impact of fecal microbiota transplantation on peripheral blood metabolites using metabolomics.
Time frame: from baseline to week 24
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Type 1 Diabetes
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xia Li, MD/PHD principal investigator
The Second Xiangya Hospital, Central South University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing fecal microbiota transplantation in people with Type 1 Diabetes, run by Second Xiangya Hospital of Central South University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xia Li, MD/PHD (+86 13974885753, lixia2014@vip.163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognition:Comparison of the average change in Z-scores for memory and executive domain-related assessments between the experimental and control groups from baseline to week 24. (time frame: from baseline to week 24). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2024.